• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

锁核酸反义寡核苷酸的肝转录谱比较:非靶介导毒性在小鼠中相关途径的证据。

Comparison of hepatic transcription profiles of locked ribonucleic acid antisense oligonucleotides: evidence of distinct pathways contributing to non-target mediated toxicity in mice.

机构信息

* Drug Safety Research and Development, Pfizer Inc., Groton, Connecticut 06340;

出版信息

Toxicol Sci. 2014 Mar;138(1):234-48. doi: 10.1093/toxsci/kft278. Epub 2013 Dec 11.

DOI:10.1093/toxsci/kft278
PMID:24336348
Abstract

Development of LNA gapmers, antisense oligonucleotides used for efficient inhibition of target RNA expression, is limited by non-target mediated hepatotoxicity issues. In the present study, we investigated hepatic transcription profiles of mice administered non-toxic and toxic LNA gapmers. After repeated administration, a toxic LNA gapmer (TS-2), but not a non-toxic LNA gapmer (NTS-1), caused hepatocyte necrosis and increased serum alanine aminotransferase levels. Microarray data revealed that, in addition to gene expression patterns consistent with hepatotoxicity, 17 genes in the clathrin-mediated endocytosis (CME) pathway were altered in the TS-2 group. TS-2 significantly down-regulated myosin 1E (Myo1E), which is involved in release of clathrin-coated pits from plasma membranes. To map the earliest transcription changes associated with LNA gapmer-induced hepatotoxicity, a second microarray analysis was performed using NTS-1, TS-2, and a severely toxic LNA gapmer (HTS-3) at 8, 16, and 72 h following a single administration in mice. The only histopathological change observed was minor hepatic hypertrophy in all LNA groups across time points. NTS-1, but not 2 toxic LNA gapmers, increased immune response genes at 8 and 16 h but not at 72 h. TS-2 significantly perturbed the CME pathway only at 72 h, while Myo1E levels were decreased at all time points. In contrast, HTS-3 modulated DNA damage pathway genes at 8 and 16 h and also modulated the CME pathway genes (but not Myo1E) at 16 h. Our results may suggest that different LNAs modulate distinct transcriptional genes and pathways contributing to non-target mediated hepatotoxicity in mice.

摘要

LNA gapmers 的开发,即用于有效抑制靶 RNA 表达的反义寡核苷酸,受到非靶介导的肝毒性问题的限制。在本研究中,我们研究了给予无毒和有毒 LNA gapmers 的小鼠的肝转录谱。重复给药后,有毒 LNA gapmer(TS-2),而不是无毒 LNA gapmer(NTS-1),导致肝细胞坏死和血清丙氨酸氨基转移酶水平升高。微阵列数据分析表明,除了与肝毒性一致的基因表达模式外,CME 途径中的 17 个基因在 TS-2 组中发生改变。TS-2 显著下调肌球蛋白 1E(Myo1E),该基因参与从质膜释放网格蛋白包被的陷窝。为了绘制与 LNA gapmer 诱导的肝毒性相关的最早转录变化图谱,我们在单次给药后 8、16 和 72 小时,使用 NTS-1、TS-2 和一种严重有毒的 LNA gapmer(HTS-3)进行了第二次微阵列分析。在所有时间点,在所有 LNA 组中仅观察到轻微的肝肥大的组织病理学变化。NTS-1 但不是 2 种有毒 LNA gapmers,在 8 和 16 小时增加了免疫反应基因,但在 72 小时不增加。TS-2 仅在 72 小时显著扰乱 CME 途径,而 Myo1E 水平在所有时间点均降低。相比之下,HTS-3 在 8 和 16 小时调节 DNA 损伤途径基因,并且在 16 小时还调节 CME 途径基因(但不调节 Myo1E)。我们的结果可能表明,不同的 LNA 调节不同的转录基因和途径,导致小鼠中非靶介导的肝毒性。

相似文献

1
Comparison of hepatic transcription profiles of locked ribonucleic acid antisense oligonucleotides: evidence of distinct pathways contributing to non-target mediated toxicity in mice.锁核酸反义寡核苷酸的肝转录谱比较:非靶介导毒性在小鼠中相关途径的证据。
Toxicol Sci. 2014 Mar;138(1):234-48. doi: 10.1093/toxsci/kft278. Epub 2013 Dec 11.
2
Development of a Method for Profiling Protein Interactions with LNA-Modified Antisense Oligonucleotides Using Protein Microarrays.利用蛋白质芯片分析与锁核酸修饰的反义寡核苷酸相互作用的蛋白质的方法的开发。
Nucleic Acid Ther. 2016 Apr;26(2):93-101. doi: 10.1089/nat.2015.0576. Epub 2015 Dec 7.
3
Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts.高亲和力缺口mer反义寡核苷酸的肝毒性是由RNase H1依赖性的超长前体mRNA转录本的混杂减少介导的。
Nucleic Acids Res. 2016 Mar 18;44(5):2093-109. doi: 10.1093/nar/gkv1210. Epub 2015 Nov 8.
4
Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides.锁核酸修饰的gapmer反义寡核苷酸引起的核糖核酸酶H1依赖性肝毒性。
Sci Rep. 2016 Jul 27;6:30377. doi: 10.1038/srep30377.
5
Role of Computationally Evaluated Target Specificity in the Hepatotoxicity of Gapmer Antisense Oligonucleotides.计算评估的靶标特异性在 Gapmer 反义寡核苷酸肝毒性中的作用。
Nucleic Acid Ther. 2018 Oct;28(5):312-317. doi: 10.1089/nat.2018.0724. Epub 2018 Aug 10.
6
Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals.含有锁核酸的反义寡核苷酸可提高效力,但在动物中会引起显著的肝毒性。
Nucleic Acids Res. 2007;35(2):687-700. doi: 10.1093/nar/gkl1071. Epub 2006 Dec 19.
7
Sequence motifs associated with hepatotoxicity of locked nucleic acid--modified antisense oligonucleotides.与锁核酸修饰反义寡核苷酸肝毒性相关的序列基序。
Nucleic Acids Res. 2014 Apr;42(8):4882-91. doi: 10.1093/nar/gku142. Epub 2014 Feb 18.
8
On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide.关于四种锁核酸核苷酸掺入抗H-Ras反义寡核苷酸后的体外和体内性质
Chembiochem. 2005 Jun;6(6):1104-9. doi: 10.1002/cbic.200400419.
9
Antiviral Efficacy of RNase H-Dependent Gapmer Antisense Oligonucleotides against Japanese Encephalitis Virus.依赖 RNase H 的 Gapmer 反义寡核苷酸对日本脑炎病毒的抗病毒功效。
Int J Mol Sci. 2023 Oct 2;24(19):14846. doi: 10.3390/ijms241914846.
10
Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4'-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer.填补锁核酸(LNA)反义寡核苷酸缺口嵌合体的空白:解锁核酸(UNA)和4'-C-羟甲基-DNA修饰对核糖核酸酶H募集及LNA缺口嵌合体疗效的影响
Mol Biosyst. 2009 Aug;5(8):838-43. doi: 10.1039/b903922h. Epub 2009 May 19.

引用本文的文献

1
Clinical Applications of Antisense Oligonucleotides in Cancer: A Focus on Glioblastoma.反义寡核苷酸在癌症中的临床应用:以神经胶质瘤为例。
Cells. 2024 Nov 11;13(22):1869. doi: 10.3390/cells13221869.
2
Antisense oligonucleotides and their applications in rare neurological diseases.反义寡核苷酸及其在罕见神经系统疾病中的应用。
Front Neurosci. 2024 Sep 23;18:1414658. doi: 10.3389/fnins.2024.1414658. eCollection 2024.
3
Specificity of oligonucleotide gene therapy (OGT) agents.寡核苷酸基因治疗(OGT)药物的特异性。
Theranostics. 2022 Oct 9;12(16):7132-7157. doi: 10.7150/thno.77830. eCollection 2022.
4
Karnovsky's fixative prevents artifacts appearing as vacuolation derived from tissue processing in kidneys treated with antisense oligonucleotide.卡诺夫斯基固定液可防止在用反义寡核苷酸处理的肾脏中,因组织处理产生空泡化而出现假象。
J Toxicol Pathol. 2021 Oct;34(4):367-371. doi: 10.1293/tox.2021-0007. Epub 2021 Jun 7.
5
Nephrotoxic antisense oligonucleotide SPC5001 induces kidney injury biomarkers in a proximal tubule-on-a-chip.抗肾毒性反义寡核苷酸 SPC5001 在近端肾小管芯片中诱导肾脏损伤生物标志物。
Arch Toxicol. 2021 Jun;95(6):2123-2136. doi: 10.1007/s00204-021-03062-8. Epub 2021 May 7.
6
A CRISPR-Cas13a Based Strategy That Tracks and Degrades Toxic RNA in Myotonic Dystrophy Type 1.一种基于CRISPR-Cas13a的策略,用于追踪和降解1型强直性肌营养不良中的毒性RNA。
Front Genet. 2020 Dec 10;11:594576. doi: 10.3389/fgene.2020.594576. eCollection 2020.
7
Mesyl phosphoramidate backbone modified antisense oligonucleotides targeting miR-21 with enhanced in vivo therapeutic potency.靶向 miR-21 的 Mesyl 膦酰胺酸骨架修饰反义寡核苷酸,具有增强的体内治疗效力。
Proc Natl Acad Sci U S A. 2020 Dec 22;117(51):32370-32379. doi: 10.1073/pnas.2016158117. Epub 2020 Dec 7.
8
Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era.精准医学时代帕金森病的分子发病机制和核酸治疗学的进展。
Med Res Rev. 2020 Nov;40(6):2650-2681. doi: 10.1002/med.21718. Epub 2020 Aug 6.
9
Identifying and Avoiding tcDNA-ASO Sequence-Specific Toxicity for the Development of DMD Exon 51 Skipping Therapy.识别并避免用于杜氏肌营养不良症第51外显子跳跃疗法开发的tcDNA-ASO序列特异性毒性。
Mol Ther Nucleic Acids. 2020 Mar 6;19:371-383. doi: 10.1016/j.omtn.2019.11.020. Epub 2019 Nov 27.
10
Smurf1 Silencing Using a LNA-ASOs/Lipid Nanoparticle System to Promote Bone Regeneration.使用 LNA-ASOs/脂质纳米颗粒系统沉默 Smurf1 以促进骨再生。
Stem Cells Transl Med. 2019 Dec;8(12):1306-1317. doi: 10.1002/sctm.19-0145. Epub 2019 Oct 21.